GSK licenses OTC Xerclear; U.S. market excluded
LONDON GlaxoSmithKline on Wednesday announced an exclusive agreement for the over-the-counter rights to Medivir’s cold sore treatment Xerclear (acyclovir and hydrocortisone) in key global markets. The trade name in the U.S. market is Lipsovir, which was approved as a prescription remedy for the prevention of cold sores in July 2009.
Under the terms of the agreement, GSK gains exclusive rights to market and distribute non-prescription Xerclear as part of the Zovirax franchise, across multiple markets, including Europe, Russia, Japan, India, Australia and New Zealand. The agreement excludes North and South America, China, South Korea and Israel.
“This alliance demonstrates GSK’s ongoing commitment to invest in and expand our OTC business. It will help strengthen our dermatology portfolio across multiple territories including several key emerging markets,” stated John Clarke, president, GSK Consumer Healthcare.
GSK will assume responsibility for funding ongoing and future development of Xerclear in all territories covered by the agreement.
Xerclear is the first and only topical herpes labialis (cold sores) treatment clinically proven to help prevent cold sore lesions appearing, GSK stated.
Visine unveils new red eye formula
MORRIS PLAINS, N.J. Visine has developed a new eye-drop formula that relieves eye redness and irritation.
New Visine maximum redness relief formula uses a special Hydroblend formula to soothe irritation and provide up to ten hours of comfort, Visine said. In line with the product launch, Visine has developed a free app for iPhone and iPod Touch — the Visine red eye remover application — that eliminates red eye from consumers’ photos in moments.
Visine maximum redness relief formula is available nationwide for $5.99 (in 0.5 fl. oz.) at food, drug and mass merchandisers.
Shiff survey: Cardiologists recommend supplements to patients
SALT LAKE CITY According to a new national survey commissioned by Schiff Nutrition — and conducted by an independent research firm — an overwhelming majority of cardiologists (91%) have recommended dietary supplements to their patients to support cardiovascular health.
The survey found that three-quarters of cardiologists said that if they had to choose one dietary supplement to specifically support the cardiovascular health, they would choose omega-3 fatty acids, far more so than antioxidants (7%), CoQ-10 (2%) and vitamin E (1%).